BPBeatriz García Paredes

Beatriz García Paredes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Beatriz García Paredes has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Proximal-to-distal gradient and its implications in differentiation and prognosis in colorectal neuroendocrine neoplasms: the RGETNE-HERACLES study

    by Germán Iglesias Álvarez, Jaume Capdevila, Rocio Garcia-Carbonero, Paula Jimenez-Fonseca, Marta Benavent, María Ángeles Vicente, Marta Llanos, Carlos López, Vicente Alonso, Rogelio García-Centeno, et al.

    Introduction: Colorectal neuroendocrine neoplasms (CR-NENs) are traditionally classified into midgut and hindgut derivatives, a binary classification that potentially oversimplifies the underlying developmental continuum. We investigated whether CR-NEN phenotype and prognosis follow a continuous proximal-to-distal gradient to identify the optimal stratification strategy. Methods: We analyzed 1,158 patients from the RGETNE registry. Anatomical location was modeled as a continuous variable using restricted cubic splines to dissect spatial trends in proliferation (Ki-67), differentiation, and survival. Prognostic performance of the continuous spatial model was formally compared with categorical approaches (right/left/rectum and midgut/hindgut) using the Akaike Information Criterion (AIC). Results: A distinct proximal-to-distal gradient was observed. The continuous spline-based model provided the superior fit for Ki-67 (R2=0.494), outperforming categorical approaches. Anatomical position was an independent prognostic factor, with risk increasing distally in localized disease (HR 1.79; 95% CI 1.31–2.45 for rectum vs. cecum) and significant mortality differences in metastatic disease (p<0.001). Adjuvant benefit was also heterogeneously distributed, being concentrated in distal segments. Despite the biological continuum, the embryological midgut–hindgut dichotomy yielded the most efficient statistical fit (lowest AIC) for predicting clinical recurrence. Conclusion: CR-NENs exhibit a topographical biological continuum. Continuous modeling is optimal for molecular research and characterizing tumor aggressiveness. However, for clinical risk stratification and trial design, the traditional discrete classifications (midgut–hindgut or anatomical segments) remain the most robust, parsimonious, and practically applicable surrogates.


  • Top Cited Papers
    Open Access

    Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort

    by E. Terán, R. Pazo, L. Caritá, M. Alsina, C. Hierro, C. Blanco, M. Reboredo, S. Landolfi, A. Zucchiatti, L. Visa, et al.


  • Open Access

    Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry

    by Carlos López-López, Eva Martínez de Castro, Ana Fernández Montes, Encarnación Jiménez Orozco, Sandra López Peraita, Ruth Vera, Paula Cerdá, Mariona Calvo, Beatriz García Paredes, Miriam Lobo de Mena, et al.

    Purpose: Characterization of the management and outcomes of patients diagnosed with hepatocellular carcinoma (HCC) and treated with systemic therapy who were included in the Spanish gastrointestinal RETUD registry. Methods/patients: This is a retrospective, registry-based, non-interventional, multicenter study conducted in Spain (NCT06711211, retrospectively registered in Dec-2024). This cohort from the RETUD registry includes adult patients diagnosed with HCC and treated with systemic therapy between Jan-2017 and Feb-2024. Sociodemographic, clinical, therapeutic and survival data are analyzed descriptively. Results: Four hundred and sixty nine patients were included (median age: 65.8 years; 90.2% males; 98.1% Caucasian). At diagnosis, 51.8% presented a clinical stage of Barcelona Clinic Liver Cancer (BCLC)-C. At the start of systemic treatment, 34.5% and 30.3% of the patients showed extrahepatic spread of the disease and main portal vein invasion, respectively. The most frequently administered first-line systemic therapies were sorafenib (57.1%), atezolizumab/bevacizumab (27.7%) and lenvatinib (7.5%). More than a third of the cohort (37.1%) received locoregional treatment at any time (before, concurrent and/or after systemic treatment). Overall, the median progression-free survival (PFS) and overall survival (OS) were 5.1 and 9.8 months, respectively. Patients receiving atezolizumab/bevacizumab showed the longest PFS (10.6 months) and OS (14.0 months) of all treatment groups and a numerically higher objective response rate (ORR) compared to the overall population (31.0% vs 12.5%). Conclusions: This study offers valuable insights into the clinical characteristics, management, and outcomes of HCC patients in Spain in a real-world setting. Our results suggest potential benefits of immunotherapy-based combinations over other available alternatives, supporting findings from interventional and real-world studies.


  • Open Access

    TTD expert consensus on emesis in gastric cancer: evidence-based strategies for prevention and treatment

    by Ana Fernández Montes, Ismael Macías Declara, Nieves Martínez Lago, Virginia Arrazubi, Beatriz García Paredes, Paula Jiménez Fonseca

    Emesis is a common complication in patients with gastric cancer (GC), resulting from both tumor progression and adverse events of antineoplastic therapies. It is estimated that up to 70% of patients experience nausea and vomiting, significantly impacting quality of life. Symptoms can lead to dehydration, malnutrition, fatigue, and emotional disturbances like anxiety and depression. Etiological factors fall into two categories. First, neoplasia-related mechanisms—gastric outlet obstruction, gastroparesis due to autonomic dysfunction, invasion of adjacent structures, presence of peritoneal carcinomatosis or malignant ascites—contribute to gastric emptying disorders. Second, antineoplastic treatments—including chemotherapy, radiotherapy, and targeted therapies—carry an inherent inducing emesis risk and can cause acute, delayed, anticipatory, breakthrough, or refractory emesis. International guidelines from the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Multinational Association of Supportive Care in Cancer (MASCC), and National Comprehensive Cancer Network (NCCN) recommend combination regimens that include 5-hydroxytryptamine type 3 receptor antagonist (anti-5-HT3), dexamethasone, neurokinin-1 receptor antagonists (anti-NK1), and, occasionally, olanzapine. Prophylaxis should be tailored to the emetic risk of the treatment and the individual characteristics of the patient, like age, sex, and pharmacogenomic factors. Pharmacological strategies should be complemented with non-pharmacological interventions to enhance therapeutic efficacy and alleviate symptoms. This consensus guide from the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) highlights the importance of multidisciplinary and individualized approaches to managing emesis associated with GC. Evidence-based therapeutic algorithms are essential to achieving these goals.


  • Open Access

    A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    by Guillem Argilés, Nuria Mulet, Manuel Valladares-Ayerbes, José M. Viéitez, Cristina Grávalos, Pilar García-Alfonso, Cristina Santos, María Tobeña, Beatriz García-Paredes, Manuel Benavides, et al.


  • CD133 + cell infusion in patients with colorectal liver metastases going to be submitted to a major liver resection (CELLCOL): A randomized open label clinical trial

    by Alejandra Garcia-Botella, Patricia Sáez-Carlin, Ramiro Méndez, Maria Paz Martin, Luis Ortega, Jose Vicente Méndez, Beatriz García-Paredes, L Diez-Valladares, Antonio Jose Torres